Correlation Engine 2.0
Clear Search sequence regions

  • antibiotics (1)
  • cohort study (1)
  • fluoroquinolones (11)
  • fosfomycin (10)
  • humans (1)
  • men (2)
  • patients (1)
  • physician (1)
  • prostate (3)
  • trometamol (8)
  • Sizes of these terms reflect their relevance to your search.

    The increasing incidence of fluoroquinolones (FQ) resistance may lower its efficacy in preventing UTI following transrectal ultrasound-guided prostate biopsy (TRUS-PB). We assessed the efficacy and safety of FQ and fosfomycin-trometamol (FT) in patients undergoing TRUS-PB. A prospective observational study was conducted between April 2017 and June 2019 and enrolled men undergoing TRUS-PB and receiving a single-dose of FQ (FQ-arm) or FT (FT-arm) for UTI prophylaxis per physician's choice. The primary efficacy endpoint was self-reported TRUS-PB UTI. We assessed baseline factors associated with UTI with logistic regression. A total of 222 men were enrolled, 141/222 (64%) received FQ, and 81/222 (36%) FT. The median age was 67.6 years [IQR, 61.4-72.1] and the Charlson score was 3 [IQR, 3-5]. The overall incidence of self-reported TRUS-PB UTI was 12% (24/197, (95%CI, 8%-17%)): 15% (17/116, (95% CI, 10%-17%)) in FQ-arm, versus 9% (7/81, 95% CI (5%-13%)) in FT-arm (RR = 0.55 (95% CI, 0.22-1.40), p-value = 0.209). No baseline characteristic was significantly associated with TRUS-PB UTI. Safety was similar between the arms: the rate of the reported adverse event was 31% (36/116, (95% CI, 25%-37%) in the FQ-arm versus 36% (28/81, (95% CI, 28%-41%)) in the FT-arm (RR = 1.17 (95% CI, 0.64-2.15), p = 0.602). TRUS-PB UTI prophylaxis with FT and FQ has similar efficacy and safety. A randomized comparison of these two antibiotics is warranted. Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.


    Tristan Delory, Annabelle Goujon, Alexandra Masson-Lecomte, Pauline Arias, Anthony Laurancon-Fretar, Béatrice Bercot, Pierre Mongiat-Artus, Jean-Michel Molina, Matthieu Lafaurie. Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021 Jan;102:269-274

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33129963

    View Full Text